Charles Schwab Investment Management Inc. Grows Stock Holdings in Arvinas, Inc. (NASDAQ:ARVN)

Charles Schwab Investment Management Inc. boosted its holdings in Arvinas, Inc. (NASDAQ:ARVN) by 1.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 536,112 shares of the company’s stock after buying an additional 5,443 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.78% of Arvinas worth $10,277,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also bought and sold shares of ARVN. KBC Group NV grew its stake in Arvinas by 77.0% in the 4th quarter. KBC Group NV now owns 2,885 shares of the company’s stock valued at $55,000 after buying an additional 1,255 shares in the last quarter. Quantbot Technologies LP grew its position in shares of Arvinas by 147.3% during the 3rd quarter. Quantbot Technologies LP now owns 4,367 shares of the company’s stock valued at $108,000 after purchasing an additional 2,601 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of Arvinas by 10.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 14,570 shares of the company’s stock valued at $279,000 after purchasing an additional 1,367 shares in the last quarter. Intech Investment Management LLC purchased a new position in shares of Arvinas during the 3rd quarter valued at $350,000. Finally, PEAK6 Investments LLC lifted its holdings in shares of Arvinas by 42.9% during the 3rd quarter. PEAK6 Investments LLC now owns 15,000 shares of the company’s stock worth $369,000 after acquiring an additional 4,500 shares during the last quarter. 95.19% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, CEO John G. Houston sold 31,338 shares of the company’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $16.72, for a total transaction of $523,971.36. Following the completion of the transaction, the chief executive officer now directly owns 1,157,480 shares of the company’s stock, valued at approximately $19,353,065.60. This represents a 2.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Ian Taylor sold 9,020 shares of the company’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $16.71, for a total transaction of $150,724.20. Following the transaction, the insider now directly owns 159,121 shares of the company’s stock, valued at approximately $2,658,911.91. This trade represents a 5.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 50,230 shares of company stock valued at $769,402. Insiders own 5.23% of the company’s stock.

Arvinas Trading Down 2.8 %

Shares of NASDAQ:ARVN opened at $8.75 on Friday. The company has a market cap of $601.76 million, a price-to-earnings ratio of -3.16 and a beta of 1.95. The company has a 50-day moving average price of $16.24 and a 200-day moving average price of $21.26. Arvinas, Inc. has a 12 month low of $7.91 and a 12 month high of $42.26.

Arvinas (NASDAQ:ARVN) last issued its quarterly earnings data on Tuesday, February 11th. The company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($1.07) by $0.44. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same quarter in the prior year, the business earned ($2.53) earnings per share. As a group, research analysts forecast that Arvinas, Inc. will post -3.81 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ARVN has been the subject of a number of research analyst reports. Wells Fargo & Company set a $26.00 price objective on shares of Arvinas and gave the stock an “overweight” rating in a report on Wednesday, March 12th. Citigroup dropped their price objective on shares of Arvinas from $28.00 to $19.00 and set a “neutral” rating for the company in a report on Friday, March 7th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arvinas in a report on Friday, February 7th. Guggenheim dropped their price objective on shares of Arvinas from $57.00 to $32.00 and set a “buy” rating for the company in a report on Thursday, March 13th. Finally, BMO Capital Markets set a $20.00 price objective on shares of Arvinas and gave the stock an “outperform” rating in a report on Wednesday, March 12th. Five equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $37.47.

Arvinas Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.